Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2017-08-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
第七届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's seventh board of directors' second meeting. It includes details about the meeting's attendance, the approval of amendments to the company's articles of association, approval of changes in accounting policies, and approval of the company's 2017 half-year report and its summary. The document also states that the full half-year report and summary are available on a designated website and newspapers, indicating that this document itself is not the full interim report but an announcement of board decisions and related approvals. The document length is short (1338 characters), and it primarily serves as a notice of board meeting resolutions rather than containing substantive financial data or the full report. Therefore, it fits best under Board/Management Information (MANG) as it announces board meeting decisions and approvals, including approval of financial reports, but does not contain the reports themselves.
2017-08-28 Chinese
2017年半年度财务报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as the 2017 semi-annual financial report (半年报) of Jinling Pharmaceutical Co., Ltd. It contains detailed financial statements, accounting policies, notes on subsidiaries, consolidation methods, and other comprehensive financial disclosures. The content includes actual financial data, accounting standards, and detailed notes typical of an interim or quarterly financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-28 Chinese
2017年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2017 半年度报告摘要' which translates to '2017 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the half-year period. It also includes management discussion on business operations, production, sales, medical services, and research development during the reporting period. The presence of comprehensive financial figures and operational analysis indicates this is a substantive interim financial report rather than a brief announcement or certification. The document length (8092 characters) supports it being a full report summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-28 Chinese
2016年年度分红派息实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an implementation announcement for the 2016 annual dividend distribution by Jinling Pharmaceutical Co., Ltd. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It references the approval of the dividend plan at the 2016 annual general meeting held on June 28, 2017, and provides specifics about tax treatment and shareholder eligibility. The document is an announcement of the dividend payment implementation rather than the dividend declaration itself or the full annual report. It does not contain financial statements or comprehensive financial data but focuses on dividend distribution details. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is short (1856 characters), consistent with a dividend announcement rather than a full report.
2017-07-20 Chinese
第七届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the seventh board of directors of Jinling Pharmaceutical Co., Ltd. It includes information about the election of the chairman, the composition of various board committees, and the appointment of senior management positions such as president, vice presidents, board secretary, financial officer, and others. It also provides biographical details of the appointed executives and contact information for the board secretary and securities affairs representative. The document is focused on changes and appointments in the company's board and senior management, with voting results and compliance statements. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements related to board and management changes rather than financial reports or other filings.
2017-06-29 Chinese
独立董事关于聘任公司高级管理人员的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding the appointment of senior management personnel at Jinling Pharmaceutical Co., Ltd. It references compliance with regulatory guidelines and company bylaws, and provides formal consent for the appointments. There are no financial statements, earnings data, or report attachments. The content focuses on management appointments and related governance matters, which aligns with announcements about changes in senior management rather than a full management report or annual report. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and does not indicate it is a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2017-06-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.